Open Access<p>Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab</p>
Author(s) -
Ran Ran,
Wenhua Huang,
Yaxin Liu,
Lin Shen,
Xiaoran Liu,
Yue Niu,
Weiyao Kong,
Shiping Bo,
Hope S. Rugo,
Sijia Lü,
Huiping Li
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s240990
Subject(s) - trastuzumab , medicine , hazard ratio , metastatic breast cancer , oncology , breast cancer , copy number variation , cancer , gastroenterology , gene , biology , confidence interval , genome , genetics
Patients with HER2-positive metastatic breast cancer (MBC) benefit from trastuzumab-based therapy but eventually develop intrinsic or acquired resistance. Whether plasma HER2 gene copy number (GCN) could predict survival after trastuzumab treatment remained controversial. We evaluated the prognostic value of plasma HER2 GCN using low-coverage whole-genome sequencing (LC-WGS).